Toll Free: 1-888-928-9744
Published: Feb, 2015 | Pages:
46 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2015', provides an overview of the Exocrine Pancreatic Insufficiency's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Exocrine Pancreatic Insufficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Exocrine Pancreatic Insufficiency and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Exocrine Pancreatic Insufficiency - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Exocrine Pancreatic Insufficiency and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Exocrine Pancreatic Insufficiency products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Exocrine Pancreatic Insufficiency pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Exocrine Pancreatic Insufficiency - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Exocrine Pancreatic Insufficiency pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Exocrine Pancreatic Insufficiency Overview 6 Therapeutics Development 7 Pipeline Products for Exocrine Pancreatic Insufficiency - Overview 7 Pipeline Products for Exocrine Pancreatic Insufficiency - Comparative Analysis 8 Exocrine Pancreatic Insufficiency - Therapeutics under Development by Companies 9 Exocrine Pancreatic Insufficiency - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Exocrine Pancreatic Insufficiency - Products under Development by Companies 13 Exocrine Pancreatic Insufficiency - Companies Involved in Therapeutics Development 14 Actavis plc 14 Anthera Pharmaceuticals� Inc. 15 Cilian AG 16 Laboratoires Mayoly Spindler S.A.S. 17 Nordmark Arzneimittel GmbH & Co. KG 18 Exocrine Pancreatic Insufficiency - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 25 Drug Profiles 27 burlulipase - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Cilase - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Enzyme to Replace Lipase for Exocrine Pancreatic Insufficiency - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 liprotamase - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 MS-1819 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 pancrelipase DR - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Exocrine Pancreatic Insufficiency - Recent Pipeline Updates 36 Exocrine Pancreatic Insufficiency - Dormant Projects 38 Exocrine Pancreatic Insufficiency - Discontinued Products 39 Exocrine Pancreatic Insufficiency - Product Development Milestones 40 Featured News & Press Releases 40 Nov 20, 2014: Anthera and Patheon Sign Manufacturing Agreement for Liprotamase Phase III Registration Trial 40 Dec 10, 2012: Aptalis Pharma Announces US Commercial Availability Of Ultresa Delayed-release Capsules 40 Aug 01, 2012: Cilian Receives �1m Grant For Development Of Cilase 41 Mar 01, 2012: Aptalis Pharma Receives FDA Approval For ULTRESA Pancrelipase Delayed Release Capsules 41 Jul 14, 2011: Aptalis Pharma Receives FDA Approval Of 25,000 Lipase-Unit Strength Of ZENPEP 42 Jun 17, 2011: Aptalis Pharma Receives FDA Approval For New Low Strength Of ZENPEP 42 Apr 15, 2011: Lilly Receives Complete Response Letter From FDA For Liprotamase For Treatment Of Exocrine Pancreatic Insufficiency 43 Feb 11, 2011: Axcan Completes Acquisition of Eurand and Commences Subsequent Offering Period 43 Jan 12, 2011: Lilly Announces FDA Panel Recommendation For Liprotamase 44 Jan 12, 2011: Eurand Announces Agreement With Nycomed for ZENPEP in Russia-CIS 44 Appendix 45 Methodology 45 Coverage 45 Secondary Research 45 Primary Research 45 Expert Panel Validation 45 Contact Us 45 Disclaimer 46
List of Tables Number of Products under Development for Exocrine Pancreatic Insufficiency, H1 2015 7 Number of Products under Development for Exocrine Pancreatic Insufficiency - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Comparative Analysis by Late Stage Development, H1 2015 10 Comparative Analysis by Clinical Stage Development, H1 2015 11 Comparative Analysis by Early Stage Development, H1 2015 12 Products under Development by Companies, H1 2015 13 Exocrine Pancreatic Insufficiency - Pipeline by Actavis plc, H1 2015 14 Exocrine Pancreatic Insufficiency - Pipeline by Anthera Pharmaceuticals� Inc., H1 2015 15 Exocrine Pancreatic Insufficiency - Pipeline by Cilian AG, H1 2015 16 Exocrine Pancreatic Insufficiency - Pipeline by Laboratoires Mayoly Spindler S.A.S., H1 2015 17 Exocrine Pancreatic Insufficiency - Pipeline by Nordmark Arzneimittel GmbH & Co. KG, H1 2015 18 Assessment by Monotherapy Products, H1 2015 19 Number of Products by Stage and Target, H1 2015 21 Number of Products by Stage and Mechanism of Action, H1 2015 23 Number of Products by Stage and Route of Administration, H1 2015 24 Number of Products by Stage and Molecule Type, H1 2015 26 Exocrine Pancreatic Insufficiency Therapeutics - Recent Pipeline Updates, H1 2015 36 Exocrine Pancreatic Insufficiency - Dormant Projects, H1 2015 38 Exocrine Pancreatic Insufficiency - Discontinued Products, H1 2015 39
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.